Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
How stripping diversity, equity and inclusion from health care may make Americans sicker - 2‘Extraordinary’ Iron Age war trumpet uncovered in England
- 3Step by step instructions to Guarantee the Life span of Your Dental Inserts: Support and Care Guide
- 4IDF continues counterterrorism operations in Gaza Strip, including destroying terror tunnels
- 5Historic underwater structure discovered by divers off French coast
- Melodic Combination d: A Survey of \Unrecorded Music Energy\ Show
- Kelsey Grammer on having a new baby at 70: 'You're just more available now'
- The Way to Recuperation: Defeating Dependence
- Figure out How to Explore Land Close to 5G Pinnacles
- Make your choice for a definitive Christmas place to get-away!
- Smooth countdown continues for Artemis II moon mission
- UN chief calls on Yemen's Houthi rebels to free all UN detainees
- CDC vaccine panel votes to remove universal hepatitis B birth dose recommendation
- Tens of thousands protest as far-right AfD forms new youth group
